MALIN CORPORATION PLC |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.9 EUR | 0.00% |
|
-1.67% | +31.11% |
| 01/05 | Malin Corp investee signs agreement with Astellas Pharma | AN |
| 28/03 | Transcript : Malin Corporation plc - Shareholder/Analyst Call |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 11Cr 10Cr 928.21Cr |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | 2.81Cr 2.59Cr 234.24Cr | Net cash position 2025 * | 2.68Cr 2.47Cr 223.63Cr | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 3 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.49% |
More Fundamentals
* Assessed data
More news
Latest transcript on Malin Corporation plc
More press releases
| 1 week | -1.67% | ||
| Current month | +9.26% | ||
| 1 month | +5.36% | ||
| 3 months | +2.61% | ||
| 6 months | +33.48% | ||
| Current year | +31.11% |
1 week
5.90
5.90
1 month
5.406.00
Current year
4.406.10
1 year
3.846.10
3 years
3.598.38
5 years
1.408.38
10 years
1.4015.37
| Managers | Title | Age | Since |
|---|---|---|---|
Andrea Stafford
DFI | Director of Finance/CFO | 54 | 01/22/01 |
Ita Finegan
ADM | Chief Administrative Officer | - | - |
Fiona Dunlevy
BRD | Director/Board Member | 41 | 01/15/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
William Daniel
CHM | Chairman | 72 | 01/15/01 |
Kirsten Drejer
BRD | Director/Board Member | 68 | 24/20/24 |
| Director/Board Member | 65 | 16/18/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/24/20 | 5.9 | 0.00% | 1 |
| 17/24/17 | 5.9 | 0.00% | 1 |
| 16/24/16 | 5.9 | 0.00% | 1 |
| 15/24/15 | 5.9 | -1.67% | 8 |
| 14/24/14 | 6 | 0.00% | 0 |
Real-time Irish S.E., May 20, 2024 at 09:25 pm IST
More quotes
Malin Corporation Plc is a company investing in and supporting highly innovative life sciences companies developing exceptional science and technology to deliver transformative outcomes for patients and create significant value for shareholders. Its purpose is to create shareholder value through the application of long-term capital and strategic support to its investee companies to enable them to reach their value potential.
Sector
Pharmaceuticals
Calendar
04/09/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.9
EUR
Average target price
11.7
EUR
Spread / Average Target
+98.39%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +31.11% | 12Cr | |
| +34.35% | 71TCr | |
| +31.04% | 58TCr | |
| -3.49% | 36TCr | |
| +20.15% | 33TCr | |
| +6.19% | 29TCr | |
| +15.09% | 24TCr | |
| -3.03% | 21TCr | |
| +10.38% | 21TCr | |
| +9.21% | 17TCr |
- Stock Market
- Equities
- MLC Stock
